NCT06192888 - A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 8, 2024

Primary Completion Date

January 8, 2028

Study Completion Date

January 8, 2028

Conditions

Mantle Cell LymphomaMCL

Interventions

DRUG

Glofitamab

IV Glofitamab

DRUG

Obinutuzumab

IV Obinutuzumab

DRUG

Lenalidomide

Oral Lenalidomide

Trial Locations (10)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Limited protocol activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (All protocol activities), Rockville Centre

11725

RECRUITING

Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities), Commack

55905

RECRUITING

Mayo Clinic (Data Collection Only), Rochester

63110

RECRUITING

Washington University (Data Collection Only), St Louis

02115

RECRUITING

Dana Farber Cancer Institute (Data Collection and Specimen Analysis), Boston

07920

RECRUITING

Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale